427 related articles for article (PubMed ID: 31473172)
1. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
4. Retinal Fluid Volatility Associated With Interval Tolerance and Visual Outcomes in Diabetic Macular Edema in the VISTA Phase III Trial.
Ehlers JP; Uchida A; Sevgi DD; Hu M; Reed K; Berliner A; Vitti R; Chu K; Srivastava SK
Am J Ophthalmol; 2021 Apr; 224():217-227. PubMed ID: 33253664
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
Moshfeghi AA; Thompson D; Berliner AJ; Saroj N
Ophthalmol Retina; 2020 May; 4(5):481-485. PubMed ID: 31924543
[TBL] [Abstract][Full Text] [Related]
6. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.
Ehlers JP; Zahid R; Kaiser PK; Heier JS; Brown DM; Meng X; Reese J; Le TK; Lunasco L; Hu M; Srivastava SK
Ophthalmol Retina; 2021 Dec; 5(12):1204-1213. PubMed ID: 33640493
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
Figueiredo N; Srivastava SK; Singh RP; Babiuch A; Sharma S; Rachitskaya A; Talcott K; Reese J; Hu M; Ehlers JP
Ophthalmol Retina; 2020 Feb; 4(2):154-163. PubMed ID: 31757691
[TBL] [Abstract][Full Text] [Related]
9. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.
Wykoff CC; Shah C; Dhoot D; Coleman HR; Thompson D; Du W; Baker K; Vitti R; Berliner AJ; Metzig C; Saroj N
Ophthalmology; 2019 Aug; 126(8):1171-1180. PubMed ID: 30946887
[TBL] [Abstract][Full Text] [Related]
13. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
14. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies.
Korobelnik JF; Lu C; Katz TA; Dhoot DS; Loewenstein A; Arnold J; Staurenghi G
Ophthalmol Retina; 2019 Aug; 3(8):663-669. PubMed ID: 31103642
[TBL] [Abstract][Full Text] [Related]
15. Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis.
Ciulla TA; Kapik B; Grewal DS; Ip MS
Ophthalmol Retina; 2021 Jul; 5(7):633-647. PubMed ID: 33130256
[TBL] [Abstract][Full Text] [Related]
16. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Quantitative Ultrawide-field Fluorescein Angiography Dynamics in the RUBY Diabetic Macular Edema Study.
Sarici K; Yordi S; Martin A; Lunasco L; Mugnaini C; Chu K; Moini H; Vitti R; Srivastava SK; Ehlers JP
Ophthalmol Retina; 2023 Jun; 7(6):543-552. PubMed ID: 36736895
[TBL] [Abstract][Full Text] [Related]
18. EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN.
Terasaki H; Shiraki K; Ohji M; Metzig C; Schmelter T; Zeitz O; Sowade O; Kobayashi M; Vitti R; Berliner A; Shiraga F
Retina; 2019 May; 39(5):938-947. PubMed ID: 29470308
[TBL] [Abstract][Full Text] [Related]
19. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
Wykoff CC; Le RT; Khurana RN; Brown DM; Ou WC; Wang R; Clark WL; Boyer DS;
Am J Ophthalmol; 2017 Jan; 173():56-63. PubMed ID: 27702624
[TBL] [Abstract][Full Text] [Related]
20. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]